Colorectal cancer (CRC) is the second leading cause of cancer–related death. Fortunately, it can be prevented 9 out of 10 times through early detection
with colonoscopy.1 Unfortunately, up to 30% of bowel preparations are inadequate, hindering detection of small and flat lesions.2
A clean colon is necessary to identify polyps and lesions, including flat lesions, which are 10 times more likely to be cancerous than polyps. Excellent
cleansing is also necessary but difficult to achieve in the ascending colon, where about 37% of flat lesions are found.3 In addition to achieving
excellent colon cleansing, an effective prep should maximize tolerability and compliance.
Timing is another key to achieving a clean colon. Recent guidelines from the American College of Gastroenterology recommend split dosing with at least
half of the dose given on the day of the colonoscopy for optimal visualization of the ascending colon and cecum, improving the quality of bowel preparations
and colonoscopy.4,5
MoviPrep is a low–volume PEG that is proven in 89% of patients to provide good or excellent cleansing in the entire colon.6 MoviPrep is proven more
tolerable than 4–L PEG solutions, and 9 out of 10 patients would take MoviPrep again for their next procedure.6,7 MoviPrep is also the first
and only PEG bowel preparation indicated for PM/AM Split Dosing™.
MOVIPREP® (PEG-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid for oral solution) is indicated for cleansing of the
colon as a preparation for colonoscopy in adults 18 years of age or older. MOVIPREP is contraindicated in patients who have had a severe hypersensitivity reaction
to any of its components. MOVIPREP should be used with caution in patients using concomitant medications that increase the risk of electrolyte abnormalities, in patients with known or suspected hyponatremia,
severe ulcerative colitis, ileus, gastrointestinal obstruction or perforation, gastric retention, toxic colitis, toxic megacolon, or glucose-6-phosphate dehydrogenase deficiency. In clinical trials, abdominal
distention, anal discomfort, thirst, nausea, and abdominal pain were the most common adverse reactions to MOVIPREP administration. MOVIPREP contains a maximum of 2.33 mg of phenylalanine per treatment.
Consult with your physician to see if this product is right for you.
For complete Prescribing Information, please click here.
For product information, adverse event reports, and product complaint reports please call:
Salix Product Information Call Center
Phone: 1-800-508-0024
Fax: 1-510-595-8183
Email: